Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q4 results

- PMLiVE

AZ forecasts growth in 2021 after revenues surge in Q4

Most recent quarter is first 'for many years' in which product sales were in excess of $7bn

- PMLiVE

Sanofi reports a profit in Q4 as Dupixent sales climb

Shares in the French pharma company climbed around 3% in premarket activity

- PMLiVE

Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4

Antiviral drug also brought in $2.8bn for the full year

Roche Basel Switzerland

Roche’s diagnostic business sales offer a bright spot in Q4

Company's pharmaceutical division sales slipped due to biosimilar competition

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

- PMLiVE

bluebird bio to separate oncology and rare diseases units

New oncology company will be led by current bluebird bio CEO Nick Leschly

- PMLiVE

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

Results presented at annual American Society of Haematology (ASH) meeting

- PMLiVE

EMA accepts application for bluebird bio’s Lenti-D in CALD

Gene therapy could become a potentially transformative treatment for cerebral adrenoleukodystrophy

- PMLiVE

EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease

Gene therapy has been given a PRIME designation

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Ex-J&J exec Denice Torres joins bluebird bio’s board

Torres brings over 25 years of executive management experience to the role

- PMLiVE

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

Novel CAR-T therapy targets heavily pre-treated myeloma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links